B1962 is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. The lead sponsor is Tasly Biopharmaceuticals Co., Ltd.. Registered phase: Phase 2. Conditions studied include Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervical Cancers.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors (ClinicalTrials.gov ↗) Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers |
Phase 2 | Not yet open |
| NCT06838546 | A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Advanced Colorectal Cancer |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Recurrent Platinum-resistant Epithelial Ovarian Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| Cervical Cancers | 1 |
| Small Cell Lung Cancer | 1 |
| Advanced Colorectal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Tasly Biopharmaceuticals Co., Ltd. | 2 |
| Register | B1962 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how B1962 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists B1962 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.